News & Analysis

Amgen reports Q4 results

8 February 2022 By Klavs Valters


Amgen Inc. (AMGN) reported its fourth-quarter financial results after the closing bell on Monday.

The US biotechnology company reported total revenue of $6.846 billion (a 3% increase from the same period in 2020), just shy of the analyst forecast of $6.868 billion.

Earnings per share was reported at $4.36 (up 26% year-over-year), beating analyst forecasts of $4.04 per share.

Total revenues reported at $26 billion in 2021 – up by 2% from the previous year.

Robert A. Bradway, Chairman, and Chief Executive Officer of Amgen commented on last year’s results: “We realized strong volume growth for many of our key products during last year.”

“These products, combined with our many pipeline opportunities, position us well for long-term growth,” Bradway added.

Amgen Inc. (AMGN) chart (Weekly)

Shares of Amgen little changed at the end of the trading day on Monday, up by 0.64% at $223.49 per share. Here is how the stock has performed in the past year –

  • 1 Month: -2.97%
  • 3 Month: +5.75%
  • Year-to-date: -0.64%
  • 1 Year: -5.91%

Amgen is the 107th largest company in the World, with a total market cap of $125.90 billion.

You can trade Amgen Inc. (AMGN) and many other stocks from the NYSE, NASDAQ, HKEX, and the ASX with GO Markets as a Share CFD.

Sources: Amgen Inc., TradingView, GO Markets MT5, CompaniesMarketCap

Ready to start trading?

Disclaimer: Articles are from GO Markets analysts and contributors and are based on their independent analysis or personal experiences. Views, opinions or trading styles expressed are their own, and should not be taken as either representative of or shared by GO Markets. Advice, if any, is of a ‘general’ nature and not based on your personal objectives, financial situation or needs. Consider how appropriate the advice, if any, is to your objectives, financial situation and needs, before acting on the advice. If the advice relates to acquiring a particular financial product, you should obtain and consider the Product Disclosure Statement (PDS) and Financial Services Guide (FSG) for that product before making any decisions.